Lifeward LTD 8-K filings

Lifeward Ltd. announced a 16% revenue increase in Q2 2026 to $6.6 million, alongside significant board and CFO transitions.

Lifeward Ltd. announced the appointment of Dr. Keith D. Rose as Chief Medical Officer, effective May 1, 2026, following his tenure in various medical affairs roles within the company.

Lifeward Ltd. announced its first quarter 2026 financial results, highlighting the successful closing of the Oratech acquisition and a $10 million financing, alongside a 33% reduction in operating cash burn year-over-year.

Lifeward Ltd. reports the termination of Vice President of Strategy and Market Access, Jeannine Lynch, effective May 3, 2026, with severance to be provided as per her employment agreement.

Lifeward Ltd. announced it has regained compliance with Nasdaq's audit committee requirements following new appointments to its board.

Lifeward Ltd. announced the completion of its acquisition of Oratech Pharma, Inc., alongside significant board changes and equity issuance.

Lifeward Ltd. received a Nasdaq notice for non-compliance with audit committee requirements following a director's resignation, but its shares continue to trade.

Lifeward Ltd. shareholders approved all six proposals at its Extraordinary General Meeting, including the issuance of shares for the Oratech Pharma acquisition and the election of new external directors.

Lifeward Ltd. completed a 1-for-12 reverse share split on February 24, 2026, to meet Nasdaq's minimum bid price requirement.

Hadar Levy, a Class I director of Lifeward Ltd., has resigned from the company's Board of Directors, effective February 24, 2026.

Lifeward Ltd. announced the acquisition of intellectual property and technology assets from Skelable Ltd. for up to $500,000, primarily through share issuance.

Lifeward Ltd. entered into a new secured promissory note with Oramed Pharmaceuticals, Inc. for up to $1.5 million at a 24% annual interest rate, secured by the company's cash.

Lifeward Ltd. received an additional 180-day extension from Nasdaq to regain compliance with the $1.00 minimum bid price requirement, pushing the deadline to August 3, 2026.

Lifeward Ltd. announced a revised board composition and an Extraordinary General Meeting to approve share issuances, director elections, and other matters related to the Oratech Pharma acquisition.

Lifeward Ltd. announced a transformative strategic partnership with Oramed Pharmaceuticals, integrating Oramed's oral drug delivery technology and securing up to $47 million in capital.

Lifeward Ltd. shareholders approved proposals to authorize a reverse share split, increase authorized share capital, and eliminate par value at an Extraordinary General Meeting.

Lifeward Ltd. announced that Joseph Turk will step down as Board Chairperson on December 31, 2025, with Robert J. Marshall Jr. appointed as his successor effective January 1, 2026.

Lifeward Ltd. announced third-quarter 2025 financial results, including a 1% revenue increase and reduced cash burn, alongside securing a $3.0 million secured promissory note from Oramed Ltd.

Lifeward Ltd. announced preliminary Q3 2025 revenue of $6.2 million and operating expenses between $5.8 million and $5.9 million, with cash reserves of $2.0 million.

Lifeward Ltd. announced its second quarter 2025 financial results, reporting a wider net loss due to a goodwill impairment charge, despite operational efficiencies and key strategic advancements.

Lifeward Ltd. announced the appointment of Almog Adar, previously VP of Finance and Chief Accounting Officer, as its new Chief Financial Officer, effective August 1, 2025.

Lifeward Ltd. received a Nasdaq deficiency notice for its ordinary shares trading below the minimum $1.00 bid price requirement, initiating a 180-day compliance period.

Lifeward Ltd. shareholders approved most proposals at their 2025 Annual Meeting, including director re-elections and a new incentive plan, but rejected equity compensation for director Randel E. Richner's consulting services.

Lifeward Ltd. has successfully closed a public offering, raising approximately $2.0 million in net proceeds through the sale of ordinary shares and accompanying warrants.

Lifeward Ltd. has expanded its Board of Directors to eight members with the appointment of Mark Grant, while current Co-CEO Larry Jasinski will resign from the Board, as the company sets its Annual General Meeting for August 1, 2025.

Lifeward Ltd. announced that Chief Financial Officer Michael Lawless will resign effective June 27, 2025, citing personal reasons and no disagreements with the company's financial practices.

Lifeward Ltd. has appointed Mark Grant as its new President and CEO, effective June 2, 2025, to drive growth and profitability.

Lifeward Ltd. reports a slight revenue decrease year-over-year for Q1 2025, but highlights progress in ReWalk adoption, AlterG growth, and improved operating expense management.

Lifeward Ltd. announces the U.S. national launch of the ReWalk 7 Personal Exoskeleton, featuring new and improved functionalities for individuals with spinal cord injury.

Lifeward Ltd. reports preliminary Q1 2025 revenue of approximately $5.0 million and the departure of its Chief Sales Officer, Charles Remsberg, effective May 30, 2025.